Lupin Limited

LUPIN

INE326A01037

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 09:50:46 16/07/2024 BST			5-day change	1st Jan Change
1,839 ^INR	+0.40%		+1.55%	+39.15%

06:01am	Lupin Sells US Commercial Women's Health Specialty Business to Evofem Biosciences	MT
07-15	Lupin Gets Establishment Inspection Report from US FDA After Dabhasa Unit, Inspection	MT

Evofem Bio.sciences, Inc. acquired Womens Health Specialty Business of Lupin Limited for $84 million.

July 14, 2024

Evofem Bio.sciences, Inc. (OTCPK:EVFM) acquired Womens Health Specialty Business of Lupin Limited (BSE:500257) for $84 million on July 15, 2024

Evofem Bio.sciences, Inc. (OTCPK:EVFM) completed the acquisition of Womens Health Specialty Business of Lupin Limited (BSE:500257) on July 15, 2024

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	LUPIN LIMITED	1,839 INR	+0.40%	+1.55%	10B
	EVOFEM BIOSCIENCES, INC.	0.0095 USD	-12.04%	-13.64%	806K

Latest news about Lupin Limited

Lupin Sells US Commercial Women's Health Specialty Business to Evofem Biosciences	05:01am	MT
Lupin Gets Establishment Inspection Report from US FDA After Dabhasa Unit, Inspection	07-15	MT
Evofem Bio.sciences, Inc. acquired Womens Health Specialty Business of Lupin Limited for $84 million.	07-14	CI
INDIA STOCKS-IT leads Indian shares to record highs	07-04	RE
India plans incentives for diabetes, obesity drug makers in 2026, government official says	06-28	RE
Indian Equities Fall on Friday, Dragged Mainly by Banking Stocks	06-28	MT
Lupin Loses Appeal Against EU Anti-Trust Fine	06-28	MT
Lupin Appoints CEO for Subsidiary Lupin Manufacturing Solutions	06-17	MT
Lupin Gets Zero Observations from US FDA After Nagpur, India Unit Inspection	06-14	MT
Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada	06-05	MT
India's pharma export sales to grow faster this year, trade body says	05-30	RE
Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research	05-27	RE
Lupin Gets Six Observations from US FDA After Somerset Unit Inspection	05-20	MT
U.S. FDA Concludes a Pre Approval Inspection at Lupin's Somerset, New Jersey Manufacturing Facility	05-19	CI
Lupin Relaunches Mirabegron ER Tablets in US	05-13	MT
Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy	05-09	MT
Lupin Limited Announces Board Appointments	05-09	CI
Jefferies Adjusts Lupin’s Price Target to INR1,535 From INR1,460 Keeps at Hold	05-08	MT
Transcript : Lupin Limited, Q4 2024 Earnings Call, May 07, 2024	05-07
Lupin's Consolidated Profit Climbs in Fiscal Q4; Shares Dip 4%	05-07	MT
Indian drugmaker Lupin misses quarterly profit estimates as costs rise	05-06	RE
Lupin Limited Recommends Dividend for the Year Ended March 31, 2024	05-06	CI
Lupin Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-06	CI
Lupin Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-06	CI
Lupin Limited Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP	05-06	CI

Chart Lupin Limited

Duration

Period

More charts

Company Profile

Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

02/08/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Lupin Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,832 INR

Average target price

1,631 INR

Spread / Average Target

-10.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LUPIN LIMITED	+39.15%	10B
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+38.93%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.60%	244B
ROCHE HOLDING AG	+5.15%	234B
NOVARTIS AG	+16.27%	226B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals

Lupin Limited

Equities

LUPIN

INE326A01037

Pharmaceuticals

Evofem Bio.sciences, Inc. acquired Womens Health Specialty Business of Lupin Limited for $84 million.

Stocks mentioned in the article

EPS Revisions